413 related articles for article (PubMed ID: 33396369)
1. The Biosimilar Landscape: An Overview of Regulatory Approvals by the EMA and FDA.
Gherghescu I; Delgado-Charro MB
Pharmaceutics; 2020 Dec; 13(1):. PubMed ID: 33396369
[TBL] [Abstract][Full Text] [Related]
2. Comparison between European Medicines Agency and US Food and Drug Administration in Granting Accelerated Marketing Authorizations for Covid-19 Medicines and their Utilized Regulations.
Ghadanian M; Schafheutle E
Ther Innov Regul Sci; 2024 Jan; 58(1):79-113. PubMed ID: 37861859
[TBL] [Abstract][Full Text] [Related]
3. 'Totality of Evidence' Approach in the Development of GP2017, an Approved Adalimumab Biosimilar.
Gaylis N; Both C; Lemke L; von Richter O; Yamauchi P
Adv Ther; 2024 May; 41(5):1795-1814. PubMed ID: 38514505
[TBL] [Abstract][Full Text] [Related]
4. Long-Term Real-World Post-approval Safety Data of Multiple Biosimilars from One Marketing-Authorization Holder After More than 18 Years Since Their First Biosimilar Launch.
Sagi S; Anjaneya P; Kalsekar S; Kottke A; Cohen HP
Drug Saf; 2023 Dec; 46(12):1391-1404. PubMed ID: 37902937
[TBL] [Abstract][Full Text] [Related]
5. Improving oncology biosimilar launches in the EU, the USA, and Japan: an updated Policy Review from the Southern Network on Adverse Reactions.
Bennett CL; Schoen MW; Hoque S; Witherspoon BJ; Aboulafia DM; Hwang CS; Ray P; Yarnold PR; Chen BK; Schooley B; Taylor MA; Wyatt MD; Hrushesky WJ; Yang YT
Lancet Oncol; 2020 Dec; 21(12):e575-e588. PubMed ID: 33271114
[TBL] [Abstract][Full Text] [Related]
6. Extrapolation and Interchangeability of Infliximab and Adalimumab in Inflammatory Bowel Disease.
Chang S; Hanauer S
Curr Treat Options Gastroenterol; 2017 Mar; 15(1):53-70. PubMed ID: 28164249
[TBL] [Abstract][Full Text] [Related]
7. The Expiry of Humira
Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
[No Abstract] [Full Text] [Related]
8. Approval of Cancer Drugs With Uncertain Therapeutic Value: A Comparison of Regulatory Decisions in Europe and the United States.
Salcher-Konrad M; Naci H; Davis C
Milbank Q; 2020 Dec; 98(4):1219-1256. PubMed ID: 33021339
[TBL] [Abstract][Full Text] [Related]
9. Cancer Therapy Approval Timings, Review Speed, and Publication of Pivotal Registration Trials in the US and Europe, 2010-2019.
Lythgoe MP; Desai A; Gyawali B; Savage P; Krell J; Warner JL; Khaki AR
JAMA Netw Open; 2022 Jun; 5(6):e2216183. PubMed ID: 35687337
[TBL] [Abstract][Full Text] [Related]
10. Biosimilars: impact of biologic product life cycle and European experience on the regulatory trajectory in the United States.
Ahmed I; Kaspar B; Sharma U
Clin Ther; 2012 Feb; 34(2):400-19. PubMed ID: 22244050
[TBL] [Abstract][Full Text] [Related]
11. Drug Development and Potential Regulatory Paths for Insulin Biosimilars.
Minocha M; Gobburu J
J Diabetes Sci Technol; 2014 Jan; 8(1):14-19. PubMed ID: 24876531
[TBL] [Abstract][Full Text] [Related]
12. Biosimilars: Rationale and current regulatory landscape.
Olech E
Semin Arthritis Rheum; 2016 Apr; 45(5 Suppl):S1-10. PubMed ID: 26947438
[TBL] [Abstract][Full Text] [Related]
13. An update on the animal studies conducted for biosimilar approvals - Regulatory requirement vs actual scenario.
Pipalava P; Patel R; Mehta M; Dahiya M; Singh I; Jose V
Regul Toxicol Pharmacol; 2019 Oct; 107():104415. PubMed ID: 31254556
[TBL] [Abstract][Full Text] [Related]
14. An update on the adalimumab biosimilar landscape following the approval of the first high-concentration biosimilar.
Fusaro E; Durez P; Wohlrab J; Lee S; SangWook Yoon ; Marotte H
Immunotherapy; 2021 Dec; ():. PubMed ID: 34865524
[TBL] [Abstract][Full Text] [Related]
15. Cost to Medicare of Delayed Adalimumab Biosimilar Availability.
Lee CC; Najafzadeh M; Kesselheim AS; Sarpatwari A
Clin Pharmacol Ther; 2021 Oct; 110(4):1050-1056. PubMed ID: 34145566
[TBL] [Abstract][Full Text] [Related]
16. Preparing for the market entry of adalimumab biosimilars in the US in 2023: A primer for specialty pharmacists.
Cisek S; Choi D; Stubbings J; Bhat S
Am J Health Syst Pharm; 2023 Sep; 80(18):1223-1233. PubMed ID: 37257054
[TBL] [Abstract][Full Text] [Related]
17. Development and regulation of biosimilars: current status and future challenges.
Tsiftsoglou AS; Ruiz S; Schneider CK
BioDrugs; 2013 Jun; 27(3):203-11. PubMed ID: 23553340
[TBL] [Abstract][Full Text] [Related]
18. Considerations related to comparative clinical studies for biosimilars.
Rathore AS; Stevenson JG; Chhabra H
Expert Opin Drug Saf; 2021 Mar; 20(3):265-274. PubMed ID: 33455482
[No Abstract] [Full Text] [Related]
19. Waiving in vivo studies for monoclonal antibody biosimilar development: National and global challenges.
Chapman K; Adjei A; Baldrick P; da Silva A; De Smet K; DiCicco R; Hong SS; Jones D; Leach MW; McBlane J; Ragan I; Reddy P; Stewart DI; Suitters A; Sims J
MAbs; 2016; 8(3):427-35. PubMed ID: 26854177
[TBL] [Abstract][Full Text] [Related]
20. Biosimilars in ulcerative colitis: When and for who?
Ilias A; Gonczi L; Kurti Z; Lakatos PL
Best Pract Res Clin Gastroenterol; 2018; 32-33():35-42. PubMed ID: 30060937
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]